telangiectasis

Summary

Summary: Permanent dilation of preexisting blood vessels (capillaries, arterioles, venules) creating small focal red lesions, most commonly in the skin or mucous membranes.

Top Publications

  1. ncbi Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis
    Vladimir Surguch
    University Eye Clinic, Franz Josef Strauss Allee 11, 93042, Regensburg, Germany
    Graefes Arch Clin Exp Ophthalmol 245:783-8. 2007
  2. doi Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis
    Raul N G Vianna
    Can J Ophthalmol 43:492-3. 2008
  3. pmc The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study
    Ronald Klein
    University of Wisconsin Madison School of Medicine and Public Health, Department of Ophthalmology and Visual Sciences, 53726, USA
    Am J Ophthalmol 150:55-62.e2. 2010
  4. ncbi Unilateral nevoid telangiectasia syndrome
    B Kreft
    Department of Dermatology and Venereology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Dermatology 209:215-7. 2004
  5. ncbi Treatment of face veins with a cryogen spray variable pulse width 1064 nm Nd:YAG Laser: a prospective study of 17 patients
    Sorin Eremia
    Division of Dermatology, UCLA, Los Angeles, California, USA
    Dermatol Surg 28:244-7. 2002
  6. ncbi Laser treatment of cutaneous vascular lesions: face and leg telangiectases
    J Hercogova
    J Eur Acad Dermatol Venereol 16:12-8. 2002
  7. ncbi Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases
    Jason R Lupton
    Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA
    Dermatol Surg 28:694-7. 2002
  8. ncbi Treatment of superficial cutaneous vascular lesions: experience with the KTP 532 nm laser
    C Clark
    Photobiology Unit, Department of Dermatology, Ninewells Hospital Medical School, University of Dundee, DD1 9SY, UK
    Lasers Med Sci 19:1-5. 2004
  9. ncbi Recent advances in laser therapy for the treatment of cutaneous vascular disorders
    W J Loo
    Department of Dermatology, Addenbrooke s NHS Trust, Cambridge, UK
    Lasers Med Sci 17:9-12. 2002
  10. ncbi Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study
    J Fernando Arevalo
    Retina and Vitreous Service, Clinica Oftalmologica Centro Caracas, Caracas, Venezuela
    Graefes Arch Clin Exp Ophthalmol 245:1673-80. 2007

Detail Information

Publications212 found, 100 shown here

  1. ncbi Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis
    Vladimir Surguch
    University Eye Clinic, Franz Josef Strauss Allee 11, 93042, Regensburg, Germany
    Graefes Arch Clin Exp Ophthalmol 245:783-8. 2007
    To describe optical coherence tomography (OCT) findings in patients with juxtafoveal retinal telangiectasis (JRT).
  2. doi Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis
    Raul N G Vianna
    Can J Ophthalmol 43:492-3. 2008
  3. pmc The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study
    Ronald Klein
    University of Wisconsin Madison School of Medicine and Public Health, Department of Ophthalmology and Visual Sciences, 53726, USA
    Am J Ophthalmol 150:55-62.e2. 2010
    ..To examine the prevalence of macular telangiectasia type 2 and lesions characterizing it...
  4. ncbi Unilateral nevoid telangiectasia syndrome
    B Kreft
    Department of Dermatology and Venereology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Dermatology 209:215-7. 2004
    ..To our knowledge, no such observations have yet been published with regards to UNTS...
  5. ncbi Treatment of face veins with a cryogen spray variable pulse width 1064 nm Nd:YAG Laser: a prospective study of 17 patients
    Sorin Eremia
    Division of Dermatology, UCLA, Los Angeles, California, USA
    Dermatol Surg 28:244-7. 2002
    ..Experience with these lasers for treatment of facial telangiectasia and periorbital reticular veins is scant...
  6. ncbi Laser treatment of cutaneous vascular lesions: face and leg telangiectases
    J Hercogova
    J Eur Acad Dermatol Venereol 16:12-8. 2002
  7. ncbi Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases
    Jason R Lupton
    Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA
    Dermatol Surg 28:694-7. 2002
    ..As a result, vascular-specific laser and light sources have been developed in an effort to treat these vessels with minimal morbidity and improved efficacy...
  8. ncbi Treatment of superficial cutaneous vascular lesions: experience with the KTP 532 nm laser
    C Clark
    Photobiology Unit, Department of Dermatology, Ninewells Hospital Medical School, University of Dundee, DD1 9SY, UK
    Lasers Med Sci 19:1-5. 2004
    ..The KTP/532 nm frequency-doubled neodymium:YAG laser is a safe and effective treatment for common superficial cutaneous vascular lesions in patients with Fitzpatrick skin types I-III...
  9. ncbi Recent advances in laser therapy for the treatment of cutaneous vascular disorders
    W J Loo
    Department of Dermatology, Addenbrooke s NHS Trust, Cambridge, UK
    Lasers Med Sci 17:9-12. 2002
    ..The literature revealed many conflicting claims. Larger and properly controlled studies are necessary to better define the role of lasers in the treatment of TLV...
  10. ncbi Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study
    J Fernando Arevalo
    Retina and Vitreous Service, Clinica Oftalmologica Centro Caracas, Caracas, Venezuela
    Graefes Arch Clin Exp Ophthalmol 245:1673-80. 2007
    ..ICG)-mediated photothrombosis (IMP) combined with intravitreal triamcinolone acetonide (IVTA) in patients with macular edema secondary to idiopathic parafoveal telangiectasis (IPFT) group 2A without choroidal neovascularization (CNV).
  11. ncbi Idiopathic macular telangiectasia
    Lawrence A Yannuzzi
    LuEsther T Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, NY 10021, USA
    Arch Ophthalmol 124:450-60. 2006
    ..To review the frequency and nature of idiopathic macular telangiectasia and to classify the disorders based on new clinical and imaging observations...
  12. ncbi Coats' disease diagnosed in adulthood
    Lindsay M Smithen
    Vitreous, Retina, Macula Consultants of New York, New York, New York, USA
    Ophthalmology 112:1072-8. 2005
    ..To investigate the manifestations and clinical course of Coats' disease diagnosed in adulthood and to describe the characteristics of patients who develop it...
  13. pmc The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes
    G Giotopoulos
    Department of Genetics, University of Leicester, Leicester LE1 7RH, UK
    Br J Cancer 96:1001-7. 2007
    ..76-60.3; P=0.000003) compared with (CC) homozygotes...
  14. ncbi Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture
    J A Shields
    Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Am J Ophthalmol 131:561-71. 2001
    ..The clinician should follow strict criteria in making the diagnosis, to avoid confusing Coats disease with other forms of exudative retinopathy...
  15. doi Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2
    Traci E Clemons
    The EMMES Corporation, Rockville, MD 20850, USA
    Ophthalmic Epidemiol 17:66-73. 2010
    ....
  16. ncbi Classification and management of Coats disease: the 2000 Proctor Lecture
    J A Shields
    Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Am J Ophthalmol 131:572-83. 2001
    ..However, poor visual outcome of 20/200 or worse commonly results. Patients who present with stages 1 to 3 Coats disease have the best visual prognosis, and patients with stages 4 and 5 have a poor visual prognosis...
  17. ncbi Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis
    Suk J Moon
    Center for Retina and Macular Disease, Winter Haven, Florida, 33880, USA
    Ophthalmic Surg Lasers Imaging 38:164-6. 2007
    ..the potential visual benefit of intravitreal bevacizumab in a patient with idiopathic juxtafoveal retinal telangiectasis refractory to focal laser treatment, an intravitreal injection of bevacizumab (1.25 mg) was given...
  18. doi Juxtafoveolar telangiectasis associated with CREST syndrome
    Valentin Huerva
    Department of Ophthalmology, University Hospital Arnau de Vilanova, Lleida, Spain
    Ocul Immunol Inflamm 16:195-7. 2008
    ..To report a case of CREST syndrome associated with juxtafoveolar telangiectasias (JT)...
  19. ncbi Resolution of severe macular oedema in adult Coat's syndrome with high-dose intravitreal triamcinolone acetonide
    R R Jarin
    The Eye Institute, Tan Tock Seng Hospital, Singapore, Republic of Singapore
    Eye (Lond) 20:163-5. 2006
    ..To report the clinical outcome of a patient who received high-dose intravitreal triamcinolone acetonide as treatment for severe macular oedema secondary to adult Coat's syndrome...
  20. ncbi Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane
    J Ruys
    Eye (Lond) 21:1433-4. 2007
  21. doi Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry
    I Maruko
    Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan
    Br J Ophthalmol 92:1488-91. 2008
    To report early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis (IJRT) using spectral domain optical coherence tomography (SD-OCT) and microperimetry.
  22. ncbi Review: coats disease: the 2001 LuEsther T. Mertz lecture
    Jerry A Shields
    Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Retina 22:80-91. 2002
  23. ncbi Chorioretinal anastomosis probably occurs infrequently in type 2A idiopathic juxtafoveolar retinal telangiectasis
    J Donald M Gass
    Arch Ophthalmol 121:1345-6. 2003
  24. ncbi Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia
    Peter Charbel Issa
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Invest Ophthalmol Vis Sci 48:3788-95. 2007
    ..To assess changes of the light increment sensitivity (LIS) of the macular area in patients with type 2 idiopathic macular telangiectasia (IMT)...
  25. doi Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia
    Pukhraj Rishi
    Sankara Nethralaya, Medical Research Foundation, 18, College Road, 600006 Chennai, Tamil Nadu, India
    Graefes Arch Clin Exp Ophthalmol 246:619-21. 2008
    ..To report the efficacy of combination photodynamic therapy and intravitreal ranibizumab for juxtafoveal, subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia (IMT)...
  26. ncbi Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis
    Clarion D Alldredge
    Associated Retinal Consultants, P C, William Beaumont Hospital, Royal Oak, Michigan 48073, USA
    Retina 23:113-6. 2003
  27. ncbi Treatment and outcome of exudative retinal detachment in Coats disease: a case report
    F Patelli
    Department of Ophthalmology, Retina Service, Villa Tiberia Hospital, Rome, Italy
    Semin Ophthalmol 19:117-8. 2004
  28. ncbi Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization
    Ghislaine Ducos De Lahitte
    Department of Ophthalmology, Hopital Lariboisiere, Assistance Publique Hopitaux de Paris, France
    Am J Ophthalmol 138:892-4. 2004
    To analyze the results of photodynamic therapy (PDT) in bilateral acquired parafoveal telangiectasis.
  29. ncbi Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis
    Vrinda S Hershberger
    University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Ophthalmic Surg Lasers Imaging 34:318-20. 2003
    ..with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis is described...
  30. pmc Familial asymptomatic macular telangiectasia type 2
    Mark C Gillies
    Save Sight Institute, Department of Clinical Ophthalmology and Eye Health, The University of Sydney, Sydney, Australia
    Ophthalmology 116:2422-9. 2009
    ..To report findings in asymptomatic family members of patients with macular telangiectasia type 2...
  31. doi Metamorphopsia in patients with macular telangiectasia type 2
    Peter Charbel Issa
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, 53127, Bonn, Germany
    Doc Ophthalmol 119:133-40. 2009
    ..To assess metamorphopsia in patients with macular telangiectasia (MacTel) type 2...
  32. ncbi Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia
    Peter Charbel Issa
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Ophthalmology 114:1736-42. 2007
    ..To report the short-term effects of intravitreal bevacizumab in patients with type 2 idiopathic macular telangiectasia (IMT)...
  33. doi Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2
    Peter Charbel Issa
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Exp Eye Res 89:25-31. 2009
    ..This disease might serve as a model to further study abnormalities of MP distribution in retinal disorders and to elucidate the mechanisms of MP deposition in the retina...
  34. pmc Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins
    Shabeeba R Hannan
    Southampton Eye Unit, Tremona Road, Southampton SO16 6YD, UK
    Br J Ophthalmol 91:1729-30. 2007
  35. ncbi [Intravitreal triamcinolone injection in the treatment of idiopathic juxtafoveal telangiectasis]
    Otacílio Oliveira Maia
    Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
    Arq Bras Oftalmol 69:941-4. 2006
    Case report of one idiopathic juxtafoveal telangiectasis (IJT) 1A patient whose right eye was treated with a 4 mg intravitreal triamcinolone acetonide injection. The outcome was evaluated by visual acuity and optic coherence tomography...
  36. doi The prevalence estimates of macular telangiectasia type 2: the Melbourne Collaborative Cohort Study
    Khin Zaw Aung
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia
    Retina 30:473-8. 2010
    ..The purpose of this study was to determine the prevalence estimates of macular telangiectasia type 2 in an Australian population based on nonmydriatic digital fundus photography...
  37. ncbi Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis
    Michael J Potter
    Department of Ophthalmology, University of British Columbia, Vancouver, BC
    Can J Ophthalmol 41:34-7. 2006
    ..rarely in those with subretinal neovascular membranes (SRNVM) due to type 2A idiopathic juxtafoveolar retinal telangiectasis (IJT)...
  38. ncbi Optical coherence tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis
    Steven M Cohen
    Department of Ophthalmology, University of South Florida School of Medicine, Tampa, USA
    Retina 27:59-66. 2007
    To determine the optical coherence tomography (OCT) findings in eyes with group 2a idiopathic juxtafoveal retinal telangiectasis (IJRT).
  39. ncbi Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis
    G C Black
    University Department of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Manchester M13 OJH, UK
    Hum Mol Genet 8:2031-5. 1999
    Coats' disease is characterized by abnormal retinal vascular development (so-called 'retinal telangiectasis') which results in massive intraretinal and subretinal lipid accumulation (exudative retinal detachment)...
  40. doi Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2
    Robert P Finger
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Invest Ophthalmol Vis Sci 50:1366-70. 2009
    ..In an investigation of their significance for reading performance, reading acuity and speed were measured and correlated with parafoveal sensitivity and fixation stability...
  41. doi Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II
    Jaclyn L Kovach
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
    Retina 29:27-32. 2009
    ..fluorescein angiographic, and optical coherence tomography outcomes in patients with perifoveal telangiectasia (PT), also referred to as macular telangiectasia, Type 2 and previously known as juxtafoveolar retinal telangiectasis group 2A.
  42. ncbi Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis
    Alain Gaudric
    AP HP, Hopital Lariboisiere, Service d Ophtalmologie, Universite Paris 7, and Centre Ophtalmologique d Imagerie et de Laser, Paris, France
    Arch Ophthalmol 124:1410-9. 2006
    To describe the changes observed with optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis.
  43. ncbi Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis
    M Cakir
    Beyoglu Eye Research and Training Hospital, Istanbul, Turkey
    Eur J Ophthalmol 16:711-7. 2006
    Parafoveal telangiectasis (PT) is a developmental or acquired microvascular abnormality of the macula. Leakage of the abnormal parafoveal capillaries leads to macular edema with subsequent decrease in visual acuity...
  44. ncbi Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis
    Rodrigo Jorge
    Department of Ophthalmology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    Graefes Arch Clin Exp Ophthalmol 245:1045-8. 2007
    ..the clinical, angiographic, and optical coherence tomography findings of a patient with subretinal neovascularization (SRN) in idiopathic juxtafoveolar retinal telangiectasis (IJRT) treated with intravitreal bevacizumab injection.
  45. doi Management of Coats disease with bevacizumab in 2 patients
    Pradeep Venkatesh
    Can J Ophthalmol 43:245-6. 2008
  46. doi Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia
    Peter Charbel Issa
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Invest Ophthalmol Vis Sci 49:1172-7. 2008
    ..To report the characteristics of confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia (type 2 IMT)...
  47. ncbi Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis
    Kenneth K W Li
    Clin Experiment Ophthalmol 33:542-4. 2005
    Idiopathic juxtafoveal telangiectasis (IJT) is one of the primary retinal telangiectasia that can result in visual impairment attributed to resultant cystoid macular oedema and rarely, choroidal neovascularization...
  48. pmc Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography
    Lelia A Paunescu
    New England Eye Center, Tufts New England Medical Center, Tufts University, Boston, Massachusetts 02111, USA
    Ophthalmology 113:48-57. 2006
    ..available OCT standard-resolution system, StratusOCT, for imaging of idiopathic juxtafoveal retinal telangiectasis (IJT); and to demonstrate that UHR OCT provides additional information on disease morphology, pathogenesis, ..
  49. ncbi Optical coherence tomography in group 2A idiopathic juxtafoveolar telangiectasis
    Vishali Gupta
    Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Ophthalmic Surg Lasers Imaging 36:482-6. 2005
    To describe the optical coherence tomographic features in patients with group 2A idiopathic juxtafoveolar telangiectasis.
  50. ncbi Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis
    Nazimul Hussain
    Smt Kanuri Santhamma Retina Vitreous Centre, L V Prasad Eye Institute, L V Prasad Marg, Andhra Pradesh, India
    Am J Ophthalmol 140:333-5. 2005
    ..To report the results of repeated bilateral sequential photodynamic therapy (PDT) with verteporfin for sub-retinal neovascularization associated with parafoveal telengiectasia...
  51. ncbi Vascular-specific laser wavelength for the treatment of facial telangiectasias
    Jacob Dudelzak
    Skin Laser and Surgery Specialists of NY and NJ, NewYork, NY 10022, USA
    J Drugs Dermatol 8:227-9. 2009
    ..The 980-nm wavelength has the potential benefits of a longer wavelength with the safety of shorter wavelengths...
  52. ncbi Treating vascular lesions
    Susanne Astner
    Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Dermatol Ther 18:267-81. 2005
    ..Different treatment modalities and the various endpoints of individual vascular lesions will be discussed...
  53. ncbi Systemic sclerosis: description and diagnostic role of the oral phenomena
    Giuseppe Alessandro Scardina
    Department of Odontostomatological Science, Oral Medicine, University of Palermo, Italy
    Gen Dent 52:42-7. 2004
    ..Sclerodermic patients were monitored to implement a secondary preventive plan for controlling oral injuries caused by developing systemic sclerosis...
  54. ncbi Optimal parameters for the treatment of leg veins using Nd:YAG lasers at 1064 nm
    W Baumler
    Department of Dermatology, University of Regensburg, 93042 Regensburg, Germany Vascular Anomalies Centre, Arkansas Children s Hospital, Little Rock, AR 72202, USA
    Br J Dermatol 155:364-71. 2006
    ..However, it is still unclear how laser parameters such as wavelength, fluence and pulse duration influence vessel destruction in leg veins...
  55. ncbi Past, present, and future: vascular lasers/light devices
    Jennifer Bucci
    Cuyahoga Falls General Hospital, Cuyahoga Falls, OH, and Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10022, USA
    J Cosmet Laser Ther 8:149-53. 2006
    ..This article provides a review of the medical and scientific literature, which concludes that newer lasers have led to increasing success and safety in the treatment of cutaneous vascular lesions...
  56. doi Cutis marmorata telangiectatica congenita: a prospective study of 27 cases and review of the literature with proposal of diagnostic criteria
    A K Kienast
    Department of Paediatric Dermatology, Catholic Children s Hospital Wilhelmstift, Hamburg, Germany
    Clin Exp Dermatol 34:319-23. 2009
    ..Cutis marmorata telangiectatica congenita (CMTC) is a congenital vascular anomaly of unknown aetiology. About 300 cases have been reported in the literature. The rate of associated anomalies varies between 20% and 70%...
  57. ncbi Unilateral nevoid telangiectasia
    Chicky Dadlani
    Department of Dermatology, New York University, USA
    Dermatol Online J 14:3. 2008
    ..This condition is a rare entity that has been most commonly reported in association with puberty, pregnancy, the use of oral contraceptives, and alcoholic cirrhosis. However, there have been case reports in otherwise healthy individuals...
  58. ncbi Cutis marmorata telangiectatica congenita and neonatal lupus
    Caroline E Heughan
    Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada
    Pediatr Dermatol 24:320-1. 2007
    ..A thorough maternal history and laboratory investigations should be considered for infants with cutis marmorata telangiectatica congenita and their mothers in order to rule out the presence of an underlying autoimmune disease...
  59. ncbi Morphologic features of group 2A idiopathic juxtafoveolar retinal telangiectasis in three-dimensional optical coherence tomography
    Hideki Koizumi
    Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan
    Am J Ophthalmol 142:340-3. 2006
    To investigate morphologic features of group 2A idiopathic juxtafoveolar retinal telangiectasis (IJRT) with three-dimensional optical coherence tomography (OCT).
  60. ncbi Unilateral nevoid telangiectasia with no estrogen and progesterone receptors in a pediatric patient
    F Sule Afsar
    Indian J Dermatol Venereol Leprol 74:163-4. 2008
  61. ncbi Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium
    Young Sun
    Department of Ophthalmology, Stanford University, 300 Pasteur Drive, Room A 157, Stanford, CA 94305, USA
    Graefes Arch Clin Exp Ophthalmol 245:1387-8. 2007
    ..The purpose was to report a case of elevated intraocular vascular endothelial growth factor (VEGF) levels in a 2-year-old boy with stage 4 Coats disease...
  62. ncbi Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia
    Subrata Mandal
    Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India
    Graefes Arch Clin Exp Ophthalmol 245:1825-9. 2007
    ..To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in the treatment of subretinal neovascularization (SRNV) secondary to type 2A idiopathic juxtafoveal telangiectasia (IJT)...
  63. ncbi Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis
    Bernadette Snyers
    Cliniques Universitaires St Luc, Universite Catholique de Louvain, Avenue Hippocrate 10, B 1200 Brussels, Belgium
    Am J Ophthalmol 137:812-9. 2004
    ..To evaluate the effect of photodynamic therapy on subfoveal neovascular membrane related to type 2A idiopathic juxtafoveolar retinal telangiectasia...
  64. ncbi Treatment of cutaneous vascular lesions using multiple-intermittent cryogen spurts and two-wavelength laser pulses: numerical and animal studies
    Wangcun Jia
    Beckman Laser Institute, University of California, Irvine, California 92612 1475, USA
    Lasers Surg Med 39:494-503. 2007
    ..In this study, the feasibility of applying multiple cryogen spurts intermittently with multiple two-wavelength laser pulses (MCS-MTWLP) was studied using numerical and animal models...
  65. ncbi Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis
    Nicholas E Engelbrecht
    Department of Ophthalmology, Emory University Eye Center, Atlanta, GA, USA
    Arch Ophthalmol 120:320-4. 2002
    To report the visual outcome in patients with a neovascular membrane (NVM) associated with idiopathic juxtafoveolar telangiectasis (IJFT).
  66. ncbi A case of Coats' disease with a peeling of premacular fibrosis after photocoagulation
    Masahiko Sugimoto
    Department of Ophthalmology, Mie University School of Medicine, Edobashi Tsu city Mie prefecture, Japan
    Acta Ophthalmol Scand 80:96-7. 2002
    ..This is the first reported case in which a distinct vitreous change was observed after premacular fibrosis peeling in Coat's disease...
  67. ncbi Nd:YAG 1064 nm laser in the treatment of facial and leg telangiectasias
    A Major
    Department of Dermatology, University of Florence, Italy
    J Eur Acad Dermatol Venereol 15:559-65. 2001
    ..The relative lack of discomfort combined with a high degree of individual satisfaction should play a part in the fairly high level of acceptance of this new form of therapy for the treatment of leg and face telangiectasias...
  68. ncbi Classification of the spectrum of Coats' disease as subtypes of idiopathic retinal telangiectasis with exudation
    M Cahill
    The Research Foundation, The Royal Victoria Eye and Ear Hospital, Dublin, Ireland
    Acta Ophthalmol Scand 79:596-602. 2001
    ..disease and other cases of differing severity were classified as one of four subtypes of idiopathic retinal telangiectasis with exudation and compared with regard to clinical outcome...
  69. ncbi Optical coherence tomography characteristics of group 2A idiopathic parafoveal telangiectasis
    Juan G Sanchez
    Retina and Vitreous Service, Clinica Oftalmologica Centro Caracas, Venezuela
    Retina 27:1214-20. 2007
    ..the optical coherence tomography (OCT) characteristics of patients with group 2A idiopathic parafoveal telangiectasis (IPFT) and to correlate them with biomicroscopic and fluorescein angiographic (FA) findings based on Gass and ..
  70. ncbi Treatment of reticular leg veins with a 1064 nm long-pulsed Nd:YAG laser
    Nayomi E Omura
    Department of Medicine Dermatology, Dartmouth Medical School, USA
    J Am Acad Dermatol 48:76-81. 2003
    ..Millisecond-pulsed Nd:YAG lasers have been developed for the treatment of reticular leg veins...
  71. ncbi Acquired unilateral nevoid telangiectasia in a healthy men
    Juliana Merheb Jordão
    Evangelical University Hospital of Curitiba, Evangelical Faculty of Parana, Curitiba, PR, Brasil
    An Bras Dermatol 85:912-4. 2010
    ..This study reports the case of a healthy young man with acquired unilateral nevoid telangiectasia, without any comorbidities, clinical and /or laboratory findings indicative of hyperestrogenism...
  72. pmc A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis
    Dimitrios Karagiannis
    Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece
    Clin Interv Aging 4:63-5. 2009
    ..Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month ..
  73. ncbi Treatment of facial telangiectasias with a diode-pumped Nd:YAG laser at 532 nm
    D A Cassuto
    Ospedale S Gerardo di Monza, Italy
    J Cutan Laser Ther 2:141-6. 2000
    ..Several other vascular lasers (argon, tunable dye, copper, krypton, etc.) are disadvantaged by the risk of hypopigmented and atrophic scars...
  74. ncbi Resolution of macular edema in idiopathic juxtafoveal telangiectasis using PDT
    Maria G Kotoula
    Department of Ophthalmology, University of Thessaly School of Medicine, Larissa, Greece
    Ophthalmic Surg Lasers Imaging 40:65-7. 2009
    A 57-year-old woman was treated by photodynamic therapy for macular edema due to idiopathic juxtafoveal telangiectasis (presumed type 1A) without subretinal neovascularization...
  75. ncbi Unilateral nevoid telangiectasia syndrome: a case report and review of the literature
    Scott F Wenson
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Dermatol Online J 17:2. 2011
    ..UNTS may be more common than previously believed, and shows some response to vascular laser therapy. Differential diagnoses include hemangioma, angioma serpiginosum, and rarely, nevus flammeus...
  76. ncbi Laser treatment with a 1064-nm laser for lower extremity class I-III veins employing variable spots and pulse width parameters
    Neil S Sadick
    Department of Dermatology, Weill Medical College of Cornell University, 772 Park Avenue, New York, NY 10021, USA
    Dermatol Surg 29:916-9. 2003
    ..The long-pulsed 1064-nm Nd:YAG laser (employing varying spot sizes, pulse widths, and fluences) has gained popularity for treating lower extremity blue and red vessels that are less than 4 mm in diameter...
  77. doi Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer
    Alan A Lewin
    Department of Radiation Oncology, Baptist Hospital of Miami, Miami, FL, USA
    Int J Radiat Oncol Biol Phys 82:2104-10. 2012
    ....
  78. doi Laser vein therapy
    Jay M Kulkin
    Women s Institute for Health PC, Atlanta, GA 30342, USA
    Obstet Gynecol Clin North Am 37:501-6, vii. 2010
    ..This article will introduce the clinician to this issue and describe treatment, which may be accomplished with the same lasers used for laser hair reduction...
  79. ncbi RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis
    Mahesh P Shanmugam
    Medical and Vision Research Foundations, Sankara Nethralaya, 18 College Road, Chennai 600 006, Tamil Nadu, India
    Indian J Ophthalmol 53:61-3. 2005
    We report a case of Type 2A idiopathic parafoveal telangiectasis treated by Photodynamic Therapy (PDT), resulting in retinal pigment epithelial (RPE) atrophy corresponding to the size of the laser spot used...
  80. ncbi Laser treatment of Coats' disease
    Stephen S Couvillion
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33136, USA
    J Pediatr Ophthalmol Strabismus 42:367-8. 2005
    ..He underwent three sessions of large-spot diode laser for the treatment of Coats' disease. Serial examinations and fundus photography documented an excellent involutional response with an improvement in visual acuity...
  81. doi Integrated clinical evaluation of Type 2A idiopathic juxtafoveolar retinal telangiectasis
    Ferdinando Bottoni
    Department of Clinical Science Luigi Sacco, Eye Clinic, Luigi Sacco Hospital, University of Milan, Milan, Italy
    Retina 30:317-26. 2010
    ..coherence tomography (OCT) findings correlated with fundus autofluorescence (FAF), confocal blue reflectance (CBR), and fluorescein angiography (FA) patterns in patients affected by Type 2A idiopathic juxtafoveolar retinal telangiectasis.
  82. ncbi Long-term juxtafoveal retinal telangiectasia
    Robert C Watzke
    Casey Eye Institute, Oregon Health and Science University, Portland, Oregon 97239 4197, USA
    Retina 25:727-35. 2005
    ..To determine the long-term natural history of idiopathic juxtafoveal telangiectasia (IJRT)...
  83. ncbi Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis
    Michael J Potter
    Department of Ophthalmology, University of British Columbia, Vancouver, British Columbia, Canada
    Am J Ophthalmol 133:149-51. 2002
    To report the outcome of a patient with a subretinal neovascular membrane secondary to idiopathic juxtafoveolar retinal telangiectasis treated with photodynamic female therapy.
  84. ncbi Treatment of CNVM secondary to idiopathic juxtafoveal retinal telangiectasis by transpupillary thermotherapy
    Kasinathan Nachiappan
    Am J Ophthalmol 139:577-8; author reply 578. 2005
  85. doi Predictors of long-term toxicity using three-dimensional conformal external beam radiotherapy to deliver accelerated partial breast irradiation
    Simona F Shaitelman
    Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA
    Int J Radiat Oncol Biol Phys 81:788-94. 2011
    ..We analyzed variables associated with long-term toxicity using three-dimensional conformal external beam radiation therapy (3D-CRT) to deliver accelerated partial breast irradiation...
  86. ncbi Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis
    Lindsay M Smithen
    Vitreous, Retina, Macula Consultants of New York, New York, USA
    Am J Ophthalmol 138:884-5. 2004
    To report combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide injection for subfoveal neovascularization secondary to bilateral idiopathic juxtafoveal telangiectasis.
  87. ncbi Macular telangiectasia: a simplified classification
    Emily Chew
    Arch Ophthalmol 124:573-4. 2006
  88. ncbi Full-thickness macular hole formation in idiopathic parafoveal telangiectasis
    Hideki Koizumi
    Vitreous, Retina, and Macula Consultants of New York, and LuEsther T Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, New York, USA
    Retina 27:473-6. 2007
    To describe the macular holes in patients with idiopathic parafoveal telangiectasis (IPT) and to propose a pathophysiologic explanation for their formation.
  89. ncbi Treatment of leg and face veins with a cryogen spray variable pulse width 1064-nm Nd:YAG laser--a prospective study of 47 patients
    S Eremia
    UCLA Division of Dermatology, Los Angeles, CA, USA
    J Cosmet Laser Ther 3:147-53. 2001
    ..For the first time it appears that there is a safe and effective treatment for 1-2-mm periorbital reticular veins. However, the use of topical anesthesia may be needed for some patients...
  90. ncbi Generalized essential telangiectasia successfully treated with high-energy, long-pulse, frequency-doubled Nd:YAG laser
    T Gambichler
    Department of Dermatology, Ruhr University Bochum, Gudrunstr 56, D 44791 Bochum, Germany
    Dermatol Surg 27:355-7. 2001
    ..Generalized essential telangiectasia is a rare cutaneous disorder with limited therapeutic options...
  91. doi Bevacizumab in the treatment of idiopathic macular telangiectasia
    Maria Andreea Gamulescu
    University Eye Clinic, Franz Joseph Strauss Allee 11, 93053, Regensburg, Germany
    Graefes Arch Clin Exp Ophthalmol 246:1189-93. 2008
    ..To describe functional and morphological long-term follow-up results in patients with idiopathic macular telangiectasia (IMT) treated with intravitreal bevacizumab...
  92. doi Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia
    P Charbel Issa
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, D 53127 Bonn, Germany
    Br J Ophthalmol 92:941-5. 2008
    ..To evaluate the effects of intravitreal bevacizumab for non-proliferative type 2 idiopathic macular telangiectasia (type 2 IMT) within a mean follow-up period of 18 months...
  93. ncbi Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis
    Dhananjay Shukla
    Retina Vitreous Service, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, 1 Anna Nagar, Madurai 625 020, Tamil Nadu, India
    Am J Ophthalmol 138:147-9. 2004
    To evaluate the efficacy and safety of transpupillary thermotherapy (TTT) for subfoveal neovascularization (SRNVM) in patients with group 2A Idiopathic Juxtafoveolar Telangiectasis (IJFT).
  94. ncbi Angioma serpiginosum: a report of 2 cases identified using epiluminescence microscopy
    T Ohnishi
    Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan
    Arch Dermatol 135:1366-8. 1999
    ..Angioma serpiginosum is a rare, acquired vascular lesion simulating purpura, and should be differentiated from purpuric dermatoses such as Henoch-Schonlein purpura...
  95. ncbi Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis
    Jose A Martinez
    Arch Ophthalmol 121:1658-9. 2003
  96. doi Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia
    Lihteh Wu
    Instituto de Cirugia Ocular, San Jose, Costa Rica
    Retina 28:314-9. 2008
    ..To report the visual outcomes and ocular complications of intravitreal triamcinolone acetonide (IVTA) in the treatment of the nonproliferative stage of type II idiopathic parafoveal telangiectasia (IPT)...
  97. doi Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia
    P Charbel Issa
    Department of Ophthalmology, University of Bonn, Germany
    Eye (Lond) 23:435-41. 2009
    ..To describe patients with full-thickness macular holes (FTMHs) and lamellar macular holes (LMHs) in association with type 2 idiopathic macular telangiectasia (type 2 IMT)...
  98. pmc Observations on the management of Coats' disease: less is more
    Robert S Adam
    Department of Ophthalmology, McMaster University, 41 1967 Main St W Hamilton, Ontario, Canada L8S 4P4
    Br J Ophthalmol 91:303-6. 2007
    ..In this article we share our experience of treating various severities of Coats' disease and focus on optimal therapy for advanced disease...
  99. doi Retinal vascular caliber and macular telangiectasia type 2
    Gabriella Tikellis
    Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Ophthalmology 116:319-23. 2009
    ..To examine the relationship of retinal vascular caliber to macular telangiectasia (MT) type 2...
  100. ncbi Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia
    Otacílio Oliveira Maia
    Retina and Vitreous Service, Department of Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
    Am J Ophthalmol 144:296-9. 2007
    ..To report the use of intravitreal bevacizumab injection for the treatment of foveal detachment in idiopathic perifoveal telangiectasia (IPT)...
  101. doi Detection of facial hypotonia and diagnosis of facioscapulohumeral dystrophy
    Veeral S Sheth
    Arch Ophthalmol 126:745-6; author reply 746. 2008

Research Grants70

  1. Molecular mechanisms of lung disease in ataxia telangiectasia
    JoAnn M Sekiguchi; Fiscal Year: 2013
    ..abstract_text> ..
  2. 14th International Workshop on Ataxia-Telangiectasia and ATM
    Richard A Gatti; Fiscal Year: 2010
    ..We also hope to encourage new young investigators to develop an interest in both clinical and basic A-T/ATM-related research. ..
  3. The function of ATM protein in the biology of the adult neuron CNS:
    Karl Herrup; Fiscal Year: 2013
    ..The exploration of these phenomena will thus have significant value for our basic biological understanding of brain function as well as its malfunction in a number of different clinically relevant situations. ..
  4. Chromatin Modifications and Vulnerability to Glutamate Toxicity
    ALEXEI D KONDRATYEV; Fiscal Year: 2010
    ..This proposal will examine these mechanisms and will lay the foundation for identification of new targets for therapy of a broad variety of neurological conditions relevant to excitotoxicity. ..
  5. MECHANISMS OF GASTROINTESTINAL GROWTH AND TRANSFORMATION
    Juanita L Merchant; Fiscal Year: 2013
    ..Collectively, these studies will establish a link between ZBP-89 and pATMS1981, in the biosynthesis and function of 5HT in response to luminal butyrate. ..
  6. ATM Controls Genomic Stability in Pluripotent Stem Cells
    JASON MARK BECKTA; Fiscal Year: 2013
    ..The goal of this proposal is to contribute to a greater understanding of processes that will impact future treatments and augment our understanding of cellular biochemistry. ..
  7. Development of a Porcine Model of Ataxia-Telangiectasia
    Christopher Rogers; Fiscal Year: 2011
    ..This project is relevant to the NIH's mission because it will provide a resource to stimulate discovery, therapeutic application, and the development of new diagnostic tools. ..
  8. Mechanism and therapy for arteriovenous malformation
    Suk Paul Oh; Fiscal Year: 2013
    ..Results from this study map provide important novel insights for developing therapeutic reagents for controlling development of AVMs. ..
  9. The Role of hPso4 in DNA Repair and Chemotherapy Resistance
    Montaser Shaheen; Fiscal Year: 2013
    ..We will deplete this E2 and evaluate if this will achieve the same chemosensitivity as depleting hPso4. This will open the opportunity to identify Ubc3 small molecule inhibitors as cancer therapy. ..
  10. Development of a Porcine Model of Ataxia-Telangiectasia
    Christopher Rogers; Fiscal Year: 2013
    ....
  11. Cyclin-Dependent Kinase Inhibition During S Phase
    Geoffrey I Shapiro; Fiscal Year: 2013
    ..abstract_text> ..
  12. The Role of PGC-1aplha in the Pathogenesis of Myotonic Dystrophy Type 1
    Xiang Fang; Fiscal Year: 2013
    ..The proposed study will provide insight into the mechanism by which mutant CUG RNA disrupts PGC-1 activity and impair Mt function, and might lead to the development of intervention through modulating PGC-1 signaling in DM1. ..
  13. Recombination Repair Complex in Human Cells
    Richard Fishel; Fiscal Year: 2013
    ....
  14. Targeting the DNA damage response pathway for the treatment of HSV esophagitis
    Oleg Alekseev; Fiscal Year: 2013
    ..These studies will impact our understanding of the molecular pathways underlying HSV-1 infection and reactivation from latency, potentially identifying novel therapeutic targets for the treatment of herpes esophagitis. ..
  15. ATM, REACTIVE OXYGEN, AND CELLULAR RESPONSES TO HYPOXIA
    MICHAEL BARRY KASTAN; Fiscal Year: 2013
    ..New insights gained could be beneficial not only to this patient population, but could also benefit patients with cancer, cardiovascular disease, and neurological disorders. ..
  16. Regulation of mTORC1 signaling by mROS and ATM
    BROOKE ELIZABETH CHRISTIAN; Fiscal Year: 2013
    ..The long-term goal of this project is to better understand the role of mROS in ATM and mTORC1 signaling, which may allow development of new therapeutic strategies for A-T. ..
  17. Mechanisms of ATM activation
    Tanya T Paull; Fiscal Year: 2013
    ..Greater understanding of the mechanisms of ATM activation is essential for our understanding of the primary cellular defense against genomic instability and tumor progression. ..
  18. Genome maintenance functions of CREB/ATF transcription factors
    RANDAL SCOT TIBBETTS; Fiscal Year: 2013
    ....
  19. Targeted Degradation of DNA Damage Response Proteins by Autophagy
    Thomas J Begley; Fiscal Year: 2013
    ..We will perform genetic, biochemical and proteomic based experiments in S. cerevisiae to test our hypothesis and to define the molecular signals that allow autophagy to target specific proteins for degradation. ..
  20. Genetic Analysis of Ataxia-telangiectasia
    DAVID WASSARMAN; Fiscal Year: 2012
    ..We have established a Drosophila A-T model that mimics features of neurodegeneration in A-T patients. Using this model we propose to identify gene targets for therapeutic approaches that protect neurons from degeneration in A-T. ..
  21. Tumor-cell-specific targets for combined hyperthermia and radiation effects
    Tej K Pandita; Fiscal Year: 2013
    ..If the proposed research is successfully carried out, the novel information generated from the proposed studies will be useful in designing tumor specific therapies. ..
  22. 15th International Workshop on Ataxia-Telangiectasia and ATM to be held in India
    Tej K Pandita; Fiscal Year: 2012
    ..This will be the first A-T Workshop that provides a forum to discuss the near term potential for applying the results from basic ATM studies to possible A-T clinical treatment trials and, in the future, other neurological diseases. ..
  23. Ataxia Telangiectasia in the CNS - Cause and Effect
    Margot Mayer Proschel; Fiscal Year: 2010
    ....
  24. ATM and DNA Damage in the Nervous System
    Peter J McKinnon; Fiscal Year: 2013
    ....
  25. Targeting the DNA Damage Response for the Treatment of Herpes Simplex Labialis
    WILLIAM DONEGAN; Fiscal Year: 2013
    ..Within the scope of the proposed project, we expect to elucidate the function(s) of ATM activation -required for productive HSV-1 infection in an in vitro and in vivo model system that mimics HSL conditions. ..
  26. In vivo Analysis of ATM-Regulated Pathways
    RANDAL SCOT TIBBETTS; Fiscal Year: 2011
    ..We are specifically interested in examining whether deregulation of CREB contributes to the manifestation of A-T-related phenotypes, including cancer, and neuron demise. ..
  27. Exploring the role of Mre11 nuclease activity in DNA repair and genome stability
    JEFFREY MICHAEL BUIS; Fiscal Year: 2010
    ..Genome maintenance is crucial to cancer prevention. This proposal aims to study the role of its unknown nuclease function in relation to its the cellular response to DNA damage. ..
  28. TGFBM2 in Development and Disease
    Rosemary J Akhurst; Fiscal Year: 2012
    ..We have identified a gene that interacts with TGFB1 in mice and humans to alter vascular disease progression. Understanding how these molecules interact may ultimately help to design new or better drugs. ..
  29. ATM FUNCTION DURING V(D)J RECOMBINATION
    Barry P Sleckman; Fiscal Year: 2013
    ..Furthermore, we will elucidate the mechanisms that lead to the frequent aberrant resolution of DNA breaks as chromosomal translocations in ATM-deficient cells. ..
  30. The Meningioma Consortium: Genome-Wide Association Study
    Elizabeth B Claus; Fiscal Year: 2013
    ..Identification of risk loci for meningioma will likely have strong etiologic significance with importance for both prevention and treatment. ..
  31. Photoreceptor Integrity Software
    Timothy J Holmes; Fiscal Year: 2012
    ..A prototype will be produced that leads to a commercial software package that is easy to use by many researchers and practitioners. ..
  32. ATM as target for malignant glioma radiosensitization.
    KRISTOFFER CARL VALERIE; Fiscal Year: 2013
    ..abstract_text> ..
  33. Penn Center for ELSI Research in Emerging Genetic Technologies in Health Care
    Reed E Pyeritz; Fiscal Year: 2012
    ....
  34. FASEB SRC on Genetic Recombination and Genome Rearrangements
    JOHN HJ PETRINI; Fiscal Year: 2011
    ..This conference brings together the principal investigators studying the mechanisms of recombination with the goal of further understanding how recombination contributes to genome stability. ..
  35. The Role of ATM in Suppression of Lymphomas
    Shan Zha; Fiscal Year: 2013
    ....
  36. Cooperative roles for Atm and Hus1 in genome maintenance
    Robert Weiss; Fiscal Year: 2009
    ..abstract_text> ..
  37. Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway
    Ferruccio Galbiati; Fiscal Year: 2013
    ....
  38. Role of the Mre11/Rad50/Nbs1 complex in DNA damage response pathways
    Xiaohua Wu; Fiscal Year: 2012
    ..These studies will ultimately help develop therapeutic interventions for human diseases associated with genome instability and cancer. ..
  39. The role of ATM in glucose transport and insulin signaling in skeletal muscle
    Jonathan S Fisher; Fiscal Year: 2010
    ..Understanding the factors that cause muscles to clear sugar from the bloodstream is vital to developing strategies to treat or prevent the high blood sugar concentrations that are the hallmark of diabetes. ..
  40. A Novel Pathway Involving ATM, PP1 and I-2
    Sankar Mitra; Fiscal Year: 2012
    ....
  41. Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas
    Xiongbin Lu; Fiscal Year: 2013
    ....
  42. Roles of Mre11 in lymphocyte development and DNA repair
    David O Ferguson; Fiscal Year: 2013
    ..These include the development of our immune system, the maintenance of genomic stability, and control of cellular growth. ..
  43. A novel protein regulating thymocyte development
    NICHOLAS R GASCOIGNE; Fiscal Year: 2010
    ..This newly discovered protein appears to regulate these processes, thus this project will uncover how this novel protein functions. ..
  44. ATDC Function in Human Pancreatic Adenocarcinoma
    Diane M Simeone; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: We propose that ATDC is a promising novel therapeutic target in pancreatic cancer because it's inactivation may lead to both reduced tumor growth and sensitization to chemotherapy. ..
  45. Neuroprotective drugs for A-T
    DAVID WASSARMAN; Fiscal Year: 2013
    ....
  46. Regulation of the ATR Checkpoint Kinase by DNA Damage
    Lee Zou; Fiscal Year: 2013
    ..These studies may significantly advance the current model of ATR activation, providing the molecular basis for future studies to reveal the full biological functions of ATR and its implications in targeted cancer therapy. ..
  47. Mechanisms of Mitotic Activation of the ATM kinase
    Sankar Mitra; Fiscal Year: 2013
    ..Dissecting the important role of ATM in mitosis may help understand many A-T phenotypes and find a cure for the disease. ..
  48. Identification of Novel Protein Phosphatases in the ATM Signaling Pathway
    Xiongbin Lu; Fiscal Year: 2010
    ....
  49. Endoglin Regulates Endothelial Survival and Capillary Tube Stability
    Nam Y Lee; Fiscal Year: 2013
    ..This hypothesis will be addressed by the objectives outlined in two specific aims. ..
  50. Molecular Mechanisms of Matrix GLA Protein (MGP)
    KRISTINA I BOSTROM; Fiscal Year: 2013
    ..If successful, the obtained information may translate into strategies for using BMP inhibitors in treating vascular disease. ..
  51. Smad2 and Smooth Muscle Differentiation from Neural Crest Stem Cells
    Shiyou Chen; Fiscal Year: 2013
    ..The results will shed new light on the pathogenesis of congenital heart disease and a number of genetic diseases such as hereditary hemorrhagic telangiectasia type 1 and type 2, which may ultimately lead to therapeutic intervention. ..
  52. Glial Dysfunction in Ataxia Telangiectasia
    Margot Mayer Proschel; Fiscal Year: 2009
    ..We propose experiments that would provide an entirely new strategy to the treatment of AT. ..
  53. Themis Regulation of Thymocyte Selection
    NICHOLAS R GASCOIGNE; Fiscal Year: 2011
    ..The important phosphorylation sites in Themis will be identified, and interactions with particular binding partners including the kinases Itk and ataxia telangiectasia mutated (ATM) will be dissected. ..
  54. Vascular Malformations of the CNS
    DEAN YAW LI; Fiscal Year: 2013
    ..By gaining insights into the basic biological pathways regulated by PDCD10, we hope to point the way to future therapies for CCM. ..
  55. Coordination of Respiration with Deglutition & Phonation in Ataxia-Telangiectasia
    Maureen Lefton Greif; Fiscal Year: 2007
    ..Furthermore, developing A- T as a model will form the basis for applying this non-invasive technology to other children with dysphagia. [unreadable] [unreadable] [unreadable]..
  56. 12th International Workshop on Ataxia-Telangiectasia and ATM
    Richard Gatti; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  57. A Topical Non Steroidal Anti-inflammatory for Rosacea
    Eduardo Perez; Fiscal Year: 2013
    ..Upon completion of the proposed aims, Signum will enter SIG990 into the Phase III clinical trials. ..
  58. Function & Purification of the Fanconi Anemia Protein C*
    Gary Kupfer; Fiscal Year: 2006
    ..Identification of new proteins and elucidation of FA pathway mechanisms promise to shed light on a novel area of cancer biology with the potential to provide direct clinical applicability. ..
  59. RISK OF CANCER IN A-T FAMILIES
    Robert Haile; Fiscal Year: 2003
    ..We propose no new mutation screening in the current proposal. We believe this is a scientifically defensible compromise and hope that it will allow us to begin this important study. ..
  60. Role of ATM in Cardiac Myocyte Loss and Myocardial Remodeling
    Krishna Singh; Fiscal Year: 2009
    ..The proposed studies, designed to investigate the role of ATM in cardiac myocyte loss and myocardial remodeling, could identify molecular targets to treat ischemic heart disease in AT patients. ..
  61. Antioxidant Therapy for Ataxia Telangiectasia
    ROBERT SCHIESTL; Fiscal Year: 2009
    ....
  62. G2 CHECKPOINT FUNCTION IN HUMAN FIBROBLASTS
    William Kaufmann; Fiscal Year: 2007
    ..following DNA replication? Does ATR sends a signal through BRCA1 to inhibit Plkl when chromatid catenations are sensed? Is defective decatenation checkpoint function associated with genetic instability in cancer? ..
  63. Biology of CHK2 Kinase In Lung Cancer
    Weixin Wang; Fiscal Year: 2005
    ....
  64. Role of ATM in Radiosensitivity of Gliomas
    Chandan Guha; Fiscal Year: 2004
    ..IV) To investigate the combined toxicity of the virus vectors, ATM attenuation and radiation therapy in cultured endothelial cells, astrocytes, oligodendrocytes, neurons and brain tissues in mice models. ..
  65. PROBING THE DNA DAMAGE RESPONSE IN VITRO
    Jean Gautier; Fiscal Year: 2006
    ..These studies will provide valuable information on how the DNA damage response can be impaired or lost in the case of cancer and will help identify drugs that influence the DNA damage response. ..
  66. Regulation of non-histone protein functions by histone deacetylases
    Edward Seto; Fiscal Year: 2010
    ..Description of changes: The objectives and hypotheses of this revised proposal remain unchanged. As a result, there are minimal changes in this revised abstract section. ..
  67. DNA STRAND BREAKS AND THE GENETIC BASIS OF LYMPHOMAS
    Gilbert Chu; Fiscal Year: 2001
    ..The long term goal is to define the genetic changes that mediate malignant progression of lymphomas. Hopefully, molecular analysis of individual lymphomas will some day lead to the cure of more patients. ..
  68. Defining a Role for ATM in the Nervous System
    Carrolee Barlow; Fiscal Year: 2004
    ..These are critical steps for defining and initiating studies of potential therapeutic strategies. ..
  69. Deregulation of the Ubiquitin/26S Proteasome Pathway in AT cells: Role of ISG15
    SHYAMAL DESAI; Fiscal Year: 2009
    ..These small molecule inhibitors are expected to prevent the ataxia in A-T patients. ..
  70. Chromatin remodeling specific interactions of ATM
    Sundaresan Venkatachalam; Fiscal Year: 2009
    ..Determining the role of ATM in modulating chromatin remodeling will allow us to formulate therapeutic approaches aimed at affecting chromatin remodeling in AT patients in the future. ..